MAGE-A4 Targeting CAR-T Cell Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung, colon, and bladder cancers, particularly those targeting MAGE-A4, face challenges in effectively stimulating a robust anti-tumor immune response due to limitations in targeting specific cancer antigens and activating immune cells.
Innovation Solution
Development of a chimeric antigen receptor (CAR) comprising specific amino acid sequences that bind to the MAGE-A4 peptide, integrated into T cells to stimulate an anti-tumor immune response, including the use of co-stimulatory domains for enhanced activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then current standard therapies are applied, but they fail to effectively stimulate a robust anti-tumor immune response
Solution Approach 1:
The patent modifies the CAR structure by changing parameters such as the extracellular domain amino acid sequence (SEQ ID NO: 10 or 13), transmembrane domain, and intracellular domain to optimize binding to MAGE-A4 peptide and enhance immune response effectiveness
Solution Approach 2:
The CAR molecule is constructed as a composite structure integrating multiple functional domains: an extracellular antigen-binding domain, a transmembrane domain for cell membrane anchoring, and an intracellular signaling domain, creating a multifunctional receptor that simultaneously provides targeting and activation capabilities
2Reliability
If CAR with specific amino acid sequences is developed, then binding to MAGE-A4 peptide is achieved, but device complexity increases
Solution Approach 1:
The CAR is divided into distinct functional segments: an extracellular domain for antigen recognition, a transmembrane domain for membrane insertion, and an intracellular domain for signal transduction. This segmentation allows each part to be optimized independently for its specific function while maintaining overall coherence
Solution Approach 2:
The CAR structure is designed to perform multiple functions within a single molecular entity: binding to MAGE-A4 peptide, anchoring to the cell membrane, and initiating intracellular signaling cascades. This multi-functionality reduces the need for separate molecular components
Data Source
AI summary
The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.